The Latest Breaking News from Obesity

Obesity levels for adults have hit 26% in Britain and 42.5% in the United States, journalist Johann Hari writes in his new book, Magic Pill. In Australia, recent data shows we’re somewhere in the middle: 31%.

Increase sharper than in any age group and is likely to be linked to soaring obesity levels, junk food and inactivity, say experts

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown in the SELECT Trial to be effective in preventing the loss of kidney function in people who are overweight or obese and have established cardiovascular disease but do not have diabetes. Read further on Dynamite News:

South Park: The End Of Obesity about Ozempic has finally landed on Paramount+ and it's bonkers. Here are the top 9 mind-blowing moments.

In the "End of Obesity" special, South Park residents want the latest semaglutides, but there's a cheaper option

The efficacy of a medication to prevent liver fat accumulation--a condition that frequently coexists with obesity and can result in dangerous fatty liver disease--has been further explored by researchers at the University of Oklahoma. Read further on Dynamite News:

Obesity prevention is cheaper long-term option, says Cambridge professor, with focus on dietary advice and exercise plans

Cathie Wood splurged millions in biotech this year on strong clinical progress, AI adoption, sales growth, wider outreach, and steady product pipelines.

Pharmaceutical CEO George Hampton discusses anti-obesity medications and the quickly moving acceleration of their affordability and accessibility.